Neuropeptides as a Marker for Chronic Headache
Authors:
- 9 March 2017
- journal article
- review article
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 21 (4) , 1-8
Abstract
Purpose of Review The purpose of this review is to revise current evidence on trigemino-vascular system (TVS) neuropeptides as potential biomarkers for chronic primary headaches, mainly for chronic migraine (CM). Recent Findings Within sensory neuropeptides, released by an activated trigeminal nerve, calcitonin gene-related peptide (CGRP) levels seem to be a good biomarker of acute migraine and somewhat sensitive and specific for CM. CGRP, however, is not increased in 20–30% of CM patients, which suggests that CGRP is not the only neuropeptide involved in migraine pain generation and maintenance. Data for other sensory neuropeptides are inconsistent (neurokinin, substance P) or absent (amylin and cholecystokinin-8). Among parasympathetic neuropeptides, vasoactive intestinal polypeptide (VIP) is increased interictally in CM, and in at least some migraine cases ictally, pituitary adenylate cyclase-activating peptide (PACAP) has been shown to be increased ictally in jugular blood, but interictal, peripheral data do not indicate such an increase, and there are no data for other parasympathetic peptides. Finally, S100B, as a potential marker of glial TVS activation, has been studied with inconsistent results in migraine patients. Summary Current data on TVS neuropeptides as potential migraine biomarkers must be taken with caution, even for the promising case of CGRP. We do not know with certainty whether increased levels are the reflection of TVS activation, the reliability and homogeneity of the different laboratory tests, or what is the influence on these measurements of the short half-life of many of these peptides or of preventive treatments. One further limitation would be whether the described increases in levels of some neuropeptides such as CGRP are specific for migraine versus other headaches.Keywords
Funding Information
- Fondos Feder, ISCIII, Ministry of Economy, Spain (PI14/00020 FISSS)
This publication has 66 references indexed in Scilit:
- Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patientsCephalalgia, 2013
- Role of VIP/PACAP in primary headachesCephalalgia, 2013
- Unilateral cranial autonomic symptoms in patients with migraineActa Neurologica Belgica, 2012
- Elevated S100B and Neuron Specific Enolase Levels in Patients with Migraine-without Aura: Evidence for Neurodegeneration?Cellular and Molecular Neurobiology, 2011
- S100B's double life: Intracellular regulator and extracellular signalBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Serum Concentrations of s100b and NSE in MigraineHeadache: The Journal of Head and Face Pain, 2009
- Vasoactive Intestinal Polypeptide Evokes Only a Minimal Headache in Healthy VolunteersCephalalgia, 2006
- Serum S100β Protein in Children With Acute Recurrent Headache: A Potentially Useful Marker for MigraineHeadache: The Journal of Head and Face Pain, 2005
- Immunoreactivity of NOS, CGRP, PACAP, SP and VIP in the trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2 of the catThe Journal of Headache and Pain, 2003
- Investigation of the structure/activity relationship of human calcitonin gene-related peptide (CGRP)Biochemical and Biophysical Research Communications, 1986